GLP1R and kidney failure: A meta-analysis including 11 large (> 500 participants) randomized trials studying the effects of GLP-1 receptor agonists on kidney outcomes reported 16% lower rates of kidney failure (HR = 0.84, 95% CI = 0.72–0.99)8.